David H. Moore

6.8k total citations · 1 hit paper
97 papers, 3.9k citations indexed

About

David H. Moore is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Surgery. According to data from OpenAlex, David H. Moore has authored 97 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Obstetrics and Gynecology, 39 papers in Reproductive Medicine and 33 papers in Surgery. Recurrent topics in David H. Moore's work include Endometrial and Cervical Cancer Treatments (48 papers), Ovarian cancer diagnosis and treatment (37 papers) and Cervical Cancer and HPV Research (19 papers). David H. Moore is often cited by papers focused on Endometrial and Cervical Cancer Treatments (48 papers), Ovarian cancer diagnosis and treatment (37 papers) and Cervical Cancer and HPV Research (19 papers). David H. Moore collaborates with scholars based in United States, Ireland and Canada. David H. Moore's co-authors include John A. Blessing, George J. Olt, David Cella, Bradley J. Monk, Samuel S. Lentz, Richard P. McQuellon, Howard T. Thaler, David S. Miller, Katherine Y. Look and Peter G. Rose and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David H. Moore

94 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

2004 479 citations David H. Moore, John A. Blessing et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David H. Moore United States	33	2.0k	1.6k	1.4k	1.1k	972	97	3.9k
Roberto Angioli Italy	42	3.0k 1.5×	2.3k 1.5×	2.8k 2.0×	747 0.7×	1.1k 1.2×	286	6.3k
Violante Di Donato Italy	37	1.6k 0.8×	949 0.6×	1.5k 1.1×	752 0.7×	813 0.8×	214	3.7k
Ali̇ Ayhan Türkiye	33	1.6k 0.8×	1.2k 0.8×	1.9k 1.4×	641 0.6×	734 0.8×	271	3.7k
Edward V. Hannigan United States	29	2.0k 1.0×	1.9k 1.2×	1.9k 1.4×	958 0.9×	875 0.9×	80	4.3k
Roy F.P.M. Kruitwagen Netherlands	37	2.0k 1.0×	1.7k 1.1×	2.3k 1.7×	469 0.4×	1.1k 1.2×	178	5.2k
S. Pecorelli Italy	34	3.5k 1.7×	1.8k 1.2×	3.5k 2.5×	1.2k 1.1×	1.3k 1.3×	97	6.8k
Ritu Salani United States	36	1.8k 0.9×	1.3k 0.8×	2.3k 1.6×	660 0.6×	1.3k 1.4×	165	4.6k
Paolo Zola Italy	36	3.1k 1.5×	1.2k 0.7×	2.6k 1.9×	969 0.9×	1.0k 1.0×	151	4.8k
Sean Kehoe United Kingdom	35	2.4k 1.2×	1.9k 1.2×	3.0k 2.2×	900 0.8×	1.4k 1.4×	146	5.8k
Innocenza Palaia Italy	36	1.4k 0.7×	885 0.6×	1.7k 1.2×	538 0.5×	966 1.0×	187	3.6k

Countries citing papers authored by David H. Moore

Since Specialization

Citations

This map shows the geographic impact of David H. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Moore more than expected).

Fields of papers citing papers by David H. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Moore. The network helps show where David H. Moore may publish in the future.

Co-authorship network of co-authors of David H. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Moore. A scholar is included among the top collaborators of David H. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Moore. David H. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tewari, Krishnansu S., Michael W. Sill, Michael J. Birrer, et al.. (2023). Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecologic Oncology. 171. 141–150. 16 indexed citations

Moore, Zena, David H. Moore, Natalie McEvoy, et al.. (2022). Preventing facial pressure injuries among health care staff working in diverse COVID‐19 care environments. International Wound Journal. 19(7). 1677–1685. 3 indexed citations

Goh, Joel, et al.. (2018). Data Uncertainty in Markov Chains: Application to Cost-Effectiveness Analyses of Medical Innovations. Operations Research. 66(3). 697–715. 20 indexed citations

Moore, Kathleen N., James Java, Peter G. Rose, et al.. (2016). Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecologic Oncology. 143(2). 294–301. 31 indexed citations

Tewari, Krishnansu S., Michael W. Sill, Bradley J. Monk, et al.. (2015). Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research. 21(24). 5480–5487. 53 indexed citations

Chase, Dana M., Helen Huang, Lari Wenzel, et al.. (2012). Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 125(2). 315–319. 36 indexed citations

Small, William, Jonathan Strauss, Anuja Jhingran, et al.. (2012). ACR Appropriateness Criteria® Definitive Therapy for Early-Stage Cervical Cancer. American Journal of Clinical Oncology. 35(4). 399–405. 11 indexed citations

Siegel, Cary, Rochelle F. Andreotti, Higinia R. Cárdenes, et al.. (2012). ACR Appropriateness Criteria® Pretreatment Planning of Invasive Cancer of the Cervix. Journal of the American College of Radiology. 9(6). 395–402. 32 indexed citations

Zollinger, Terrell W., et al.. (2011). Surgical staging of endometrial cancer: robotic versus open technique outcomes in a contemporary single surgeon series. Journal of Robotic Surgery. 5(2). 109–114. 8 indexed citations

10.

Moore, David H.. (2009). Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?. Gynecologic Oncology. 113(3). 379–383. 20 indexed citations

11.

Moore, David H., Chunqiao Tian, Bradley J. Monk, et al.. (2009). Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 116(1). 44–49. 115 indexed citations

12.

Schilder, Jeanne M., et al.. (2006). The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. International Journal of Gynecological Cancer. 16(2). 496–500. 40 indexed citations

13.

Rose, Peter G., Stacy Nerenstone, Mark F. Brady, et al.. (2004). Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. New England Journal of Medicine. 351(24). 2489–2497. 245 indexed citations

14.

Moore, David H., James Kauderer, Jeffrey G. Bell, John P. Curtin, & Linda Van Le. (2004). An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecologic Oncology. 94(2). 368–374. 34 indexed citations

15.

Montana, Gustavo S., Gillian Thomas, David H. Moore, et al.. (2000). Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. International Journal of Radiation Oncology*Biology*Physics. 48(4). 1007–1013. 124 indexed citations

16.

Moore, David H., et al.. (1998). Gynecologic cancers metastatic to the breast. Journal of the American College of Surgeons. 187(2). 178–181. 45 indexed citations

17.

Moore, David H., et al.. (1995). A Phase I Study of Intraperitoneal Interferon-α2band Intravenouscis-Platinum plus Cyclophosphamide Chemotherapy in Patients with Untreated Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Pilot Study. Gynecologic Oncology. 59(2). 267–272. 8 indexed citations

18.

Look, Katherine Y., et al.. (1995). Intraperitoneal 5-fluorouracil for pseudomyxoma peritoneii. International Journal of Gynecological Cancer. 5(5). 361–365. 3 indexed citations

19.

Adler, Michael, et al.. (1991). Regulation of acetylcholine hydrolysis in canine tracheal smooth muscle. European Journal of Pharmacology. 205(1). 73–79. 18 indexed citations

20.

Williams, Stephen D., John A. Blessing, David H. Moore, H D Homesley, & Leon L. Adcock. (1989). Cisplatin, Vinblastine, and Bleomycin in Advanced and Recurrent Ovarian Germ-Cell Tumors. Annals of Internal Medicine. 111(1). 22–27. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact